Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07445490) titled 'Translational Potential of ex Vivo Gene Therapy in GM2 Gangliosidosis' on Feb. 25.
Study Type: Observational
Primary Sponsor: Assistance Publique - Hopitaux de Paris
Condition:
Tay-Sachs Disease Ganglioside
Sandhoff Disease Ganglioside
Intervention:
Biological: blood sample
Recruitment Status: Not recruiting
Date of First Enrollment: May 2026
Target Sample Size: 6
Countries of Recruitment:
France
To know more, visit https://clinicaltrials.gov/study/NCT07445490
Published by HT Digital Content Services with permission from Health Daily Digest....